CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical science during his year in office. He talks specifically about new research on using involved field radiation in patients with high-risk Hodgkin’s Lymphoma, and about three of the key presentations given at the ASCO Plenary Session:
– Emtansine: a new immuno-conjugate is proof of principle and a new option for HER2 positive metastatic breast cancer
– A new tyrosine kinase inhibitor, regorafenib, is a life giving option for patients with imatinib resistant GIST
– A drug developed in the old East Germany, bendamustine, was found to be more effective and less toxic than CHOP in patients with indolent lymphomas.
LISTEN
[audio:https://www.audiomedica.com/podcasting/news/120616MichaelLinkLoResPODCAST.mp3]
